Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Pigmentary retinopathy, Postaxial polydactyly, and Obesity; and very common findings: Intellectual disability. 11 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 1 | Pigmentary retinopathy |
MKKS encodes MKKS centrosomal shuttling protein (570 aa). Probable molecular chaperone that assists the folding of proteins upon ATP hydrolysis. Highest expression in Brain Cerebellar Hemisphere (26.9 TPM) and Brain Cerebellum (22.2 TPM).
Bardet-Biedl syndrome 6 is associated with mutations in the MKKS gene on chromosome 20.
The MKKS protein participates in p38 MAPK activation by VEGFR, Activation of p38 alpha/beta MAPK, and Formation of the BBSome pathways.
MKKS is classified as a druggable target with score 0.0.
No consensus clinical diagnostic criteria for McKusick-Kaufman syndrome (MKS) have been published.
Diagnosis of McKusick-Kaufman syndrome (MKS) should be suspected in individuals with the following features.
In females
Hydrometrocolpos (HMC)*
Postaxial polydactyly (PAP)**
No approved treatments are currently available for Bardet-Biedl syndrome 6. The disease remains an area of unmet medical need.
No clinical practice guidelines for MKS have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with McKusick-Kaufman syndrome (MKS), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with McKusick-Kaufman Syndrome (MKS)
Table 6.
Recommended Surveillance for Individuals with McKusick-Kaufman Syndrome (MKS)
System/Concern | Evaluation | Frequency
| Watch for later complications of surgery for HMC, incl recurrent urinary tract infections re-stenosis infection of vaginal tract. | No monitoring; prompt eval of symptoms signs of abdominal distention
No clinical trials have been registered for Bardet-Biedl syndrome 6.
16 publications have been identified in PubMed for Bardet-Biedl syndrome 6. Research spans Case Report / Case Series (31%), Epidemiology / Natural History (25%), and Basic Science / Preclinical (19%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 31% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 4:32 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Bardet-Biedl syndrome 6
1 |
Diabetes mellitus |
Kidneys and urinary system | 1 | Renal cyst |
Brain and nerves | 1 | Intellectual disability |
McKusick-Kaufman syndrome (MKS), defined as hydrometrocolpos (HMC) and postaxial polydactyly (PAP) without the development of the age-dependent features of BBS, was first diagnosed in a large Amish family . Although the MKS phenotype is very rare, it has been presumed to be pan ethnic following descriptions of HMC in association with polydactyly in numerous ancestries. In the Amish population, variable expressivity for MKS has been described: 70% of affected females have HMC, 60% of affected individuals of both sexes have PAP, and 15% of affected individuals of both sexes have congenital heart disease (CHD) . Of note, many individuals with HMC and PAP diagnosed as having MKS have been reported at an age too young to manifest the age-dependent features of BBS . The true incidence of physical findings associated with the MKS phenotype alone is therefore unknown. shows the most frequent associated features in 49 individuals of Amish and non-Amish ethnicity who were diagnosed with MKS; 75% were diagnosed at birth and 98% by age six months . Of these individuals, 44 were female and five were male. No similar large studies have been realized more recently and the majority of recent case reports have comprised single individuals with HMC reported in the first year of life . The degree of similarity of the phenotype between the Amish and non-Amish population is unclear and has not been systematically studied; in addition, it is not known if these individuals would have developed manifestations of BBS as they aged. The incidence of genital findings in males has also been difficult to establish outside the Amish population due to the rarity of the condition, but in 11 males who had affected sisters or other female relatives diagnosed with MKS, polydactyly was present in all cases and only one had genital abnormalities comprising cryptorchidism and hypospadias ; however, the incidence of BBS among these individuals is not known. Table 2. Phenotypic Features of Individuals with McKusick-Kaufman Syndrome (MKS) Finding | # of Individuals (%) Genitourinary malformations in females
HMC | 42/44 (95%) |
|---|---|
affected | Hands only |
anomalies | Syndactyly |
malformations | Various (See .) |
anomalies | Hydronephrosis |
GI malformations | Imperforate anus |
Source: GeneReviews — "McKusick-Kaufman Syndrome"
No genotype-phenotype correlations for MKKS have been identified.
Source: GeneReviews — "McKusick-Kaufman Syndrome"
Non-penetrance has been estimated to occur in at least 9% of affected Amish males and 3% of affected Amish females . Determination of penetrance in the non-Amish population has not yet been possible due to the rarity of the syndrome.
Source: GeneReviews — "McKusick-Kaufman Syndrome"
Congenital heart disease (CHD)
In males
Genital malformations (most commonly hypospadias, cryptorchidism, and chordee)
PAP**
CHD
In all
Insufficient manifestations of overlapping syndromes, such as Bardet-Biedl syndrome (BBS) for a diagnosis of this syndrome or another condition
Family history typically consistent with autosomal recessive inheritance (e.g., affected sibs and/or parental consanguinity and unaffected parents). Absence of a known family history does not preclude the diagnosis.
Source: GeneReviews — "McKusick-Kaufman Syndrome"
Bardet-Biedl syndrome (BBS) is a multisystem non-motile ciliopathy primarily characterized by retinal rod-cone dystrophy, truncal obesity and related complications, postaxial polydactyly, cognitive impairment, hypogonadotropic hypogonadism and/or genitourinary malformations, and renal malformations and/or renal parenchymal disease (for overview, see Bardet-Biedl Syndrome Overview). Overlap with MKS occurs due to the finding of HMC (in females), genital malformations in males, and postaxial polydactyly and congenital heart disease in both conditions. At least 26 genes are known to be associated with BBS. Pathogenic variants in MKKS account for an estimated 6.3% of all BBS (see BBS Overview). The genital malformations associated with MKS, including HMC, vaginal atresia, and cryptorchidism, have also been associated with BBS-related genes including BBS2, BBS6, BBS10, and BBS12, suggesting that these features are not MKKS/BBS6 specific . Note: Although several reports have described BBS phenotypes with three pathogenic variants and at least one variant involving the MKKS locus , triallelic inheritance has been refuted in other studies and is not currently considered a typical inheritance pattern for either MKS or BBS . illustrates the phenotypic overlap between MKS and BBS (+ = major feature; ± = minor feature). Table 3. Phenotypic Overlap Between McKusick-Kaufman Syndrome and Bardet-Biedl Syndrome
Clinical Feature | MKS | BBS |
|---|---|---|
Hydrometrocolpos in females | + | ± |
Congenital heart disease | + | ± |
Polydactyly | + | + Retinitis pigmentosa |
Source: GeneReviews — "McKusick-Kaufman Syndrome"
Genetic testing for MKKS is available. Testing is considered confirmatory for diagnosis.
System/Concern | Evaluation | Comment |
|---|---|---|
malformations | Pelvic ultrasound | In females; in males, inspection of the genitalia should be performed. Polydactyly |
syndactyly | Skeletal radiographs to detect osseous polydactyly syndactyly | Provide referral to surgical specialist as needed. Cardiac |
malformation | Echocardiogram | Specialist referral as appropriate Possible Bardet- Biedl syndrome |
(BBS)2 | Assessment of height, weight, head circumference initiation of a carefully maintained growth chart to document obesity | If obesity or short stature present, this may indicate a diagnosis of BBS Determination of developmental status by standard screening tools to detect DD |
counseling | By genetics professionals1 | To inform affected persons families re nature, MOI, implications of MKS to facilitate medical personal decision making DD = developmental delay; ERG = electroretinogram; MOI = mode of inheritance 1. |
Treatment of Manifestations in Individuals with McKusick-Kaufman Syndrome (MKS) Manifestation/Concern | Treatment | Considerations/Other |
Hydrometrocolpos | Prompt surgical repair of obstruction drainage of accumulated fluid | Hydrometrocolpos can also present after neonatal period. |
Polydactyly syndactyly | Standard treatment | Congenital heart defects Renal anomalies Anal anomalies Hirschsprung disease Surveillance Table 6. |
Recommended Surveillance for Individuals with McKusick-Kaufman Syndrome (MKS) System/Concern | Evaluation | Frequency |
Hydrometrocolpos | Watch for later complications of surgery for HMC, incl recurrent urinary tract infections re-stenosis infection of vaginal tract. | No monitoring; prompt eval of symptoms signs of abdominal distention Possible Bardet- Biedl syndrome1 |
(BBS) | Serial growth measurement to track height weight to document obesity that can occur w/BBS | Annually until at least age 5 yrs Developmental assessments to detect developmental disabilities that can occur w/BBS If renal anomaly present, monitor renal function blood pressure. |
Source: GeneReviews — "McKusick-Kaufman Syndrome"
In the newborn with severe HMC, care with anesthesia in the neonatal period is appropriate, as HMC can cause diaphragmatic compression .
Source: GeneReviews — "McKusick-Kaufman Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "McKusick-Kaufman Syndrome"
View trials for Bardet-Biedl syndrome 6
Biedl syndrome1
(BBS) | Serial growth measurement to track height weight to document obesity that can occur w/BBS | Annually until at least age 5 yrs
Developmental assessments to detect developmental disabilities that can occur w/BBS
Regular ophthalmologic exam ERG (if appropriate) to evaluate for visual signs symptoms of RP | Annually after age 5 yrs
If renal anomaly present, monitor renal function blood pressure. | Frequency of follow up of renal anomalies per specialist
Monitor for development of severe constipation w/referral for rectal biopsy to exclude Hirschsprung disease. | Review at well child health exams
ERG = electroretinogram; RP = retinitis pigmentosa
1. A subset of those with a diagnosis of MKS as infants may with age develop findings that lead to revision of the diagnosis to BBS.
Source: GeneReviews — "McKusick-Kaufman Syndrome"
Phenotype severity distribution: 3 always present features, 1 very common feature, 2 common features.
4 |
25% |
Laboratory research | 3 | 19% |
Clinical study results | 2 | 13% |
Other research | 1 | 6% |
Research summaries | 1 | 6% |
Jena D (2026). [PMID: 41641302](https://pubmed.ncbi.nlm.nih.gov/41641302/). *AACE Endocrinol Diabetes*. [Case Report / Case Series]
Pons MR (2026). [PMID: 41894554](https://pubmed.ncbi.nlm.nih.gov/41894554/). *Obes Facts*. [Case Report / Case Series]
Mahler EA (2026). [PMID: 41238926](https://pubmed.ncbi.nlm.nih.gov/41238926/). *Ophthalmologie*. [Other]
Seyedtaghia MR (2026). [PMID: 40252141](https://pubmed.ncbi.nlm.nih.gov/40252141/). *Biochem Genet*. [Epidemiology / Natural History]
Varughese RS (2026). [PMID: 42044156](https://pubmed.ncbi.nlm.nih.gov/42044156/). *J Clin Endocrinol Metab*. [Clinical Trial Publication]
Wang L (2026). [PMID: 41703510](https://pubmed.ncbi.nlm.nih.gov/41703510/). *BMC Ophthalmol*. [Case Report / Case Series]
Hühne T (2026). [PMID: 40903014](https://pubmed.ncbi.nlm.nih.gov/40903014/). *J Clin Endocrinol Metab*. [Epidemiology / Natural History]
Fatima S (2025). [PMID: 41418239](https://pubmed.ncbi.nlm.nih.gov/41418239/). *J Pak Med Assoc*. [Basic Science / Preclinical]
Fan X (2025). [PMID: 39856360](https://pubmed.ncbi.nlm.nih.gov/39856360/). *Sci Rep*. [Basic Science / Preclinical]
Argente J (2025). [PMID: 39549719](https://pubmed.ncbi.nlm.nih.gov/39549719/). *Lancet Diabetes Endocrinol*. [Clinical Trial Publication]
AI-curated news mentioning Bardet-Biedl syndrome 6
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.